Moleculin Biotech, Inc. MBRX
$0.61
+7.16%
at last close
Market Cap$4.35 million
P/E Ratio—
Div Yield—
Volume1.54M
52-Week Range
$0.16$24.00
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $22.00 (+3493.6% upside)
Key Stats
- Today's Range
- $0.58 – $0.64
- 50-Day Range
- $0.16 – $3.69
- 52-Week Range
- $0.16 – $24.00
- Volume
- 1.54 million shs
- Average Volume
- 1.58 million shs
- Market Cap
- $4.35 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.29
- Price / Sales
- —
Short Interest
- Short Interest
- 21.18%
- Days to Cover
- 5.24
Financials (TTM)
- Revenue
- —
- Net Income
- $-40,501,000
- Net Margin
- —
- Return on Equity
- -266.75%
- Debt-to-Equity
- —
About Moleculin Biotech, Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Related Stocks
Compare head-to-head: MBRX vs LLY·MBRX vs JNJ·MBRX vs ABBV·MBRX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.